Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less

Article Abstract:

A protease inhibitor combined with two nucleoside analogs seems to be more effective than the nucleoside analogs alone in preventing the progression of HIV infection. These are all drugs used to treat HIV infection. A total of 1,156 HIV-infected patients were randomly assigned to take the nucleoside analogs zidovudine and lamivudine alone or combined with the protease inhibitor indinavir. The group taking all three drugs had half the risk of progressing to AIDS or dying compared to those taking the nucleoside analogs. They also experienced greater increases in their CD4 cell counts and greater decreases in HIV RNA levels.

Author: Fischl, Margaret A., Hammer, Scott M., Demeter, Lisa M., Currier, Judith S., Hughes, Michael D., Balfour, Henry H., Jr., Grimes, Janet M., Eron, Joseph J., Jr., Squires, Kathleen E., Chodakewitz, Jeffrey A., Feinberg, Judith E., Deyton, Lawrence R.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1997
Evaluation, Product/Service Evaluation, Protease inhibitors, Zidovudine, Lamivudine, Indinavir (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Management of newly diagnosed HIV infection

Article Abstract:

A case study of a 25-year-old previously healthy woman who was found to have a positive test for human immunodeficiency virus type 1 (HIV-1) antibody is presented. Experts suggest that patients with newly diagnosed HIV infection, the initial emphasis should be on counseling with regard to the disease process, limiting the risk of secondary transmission.

Author: Hammer, Scott M.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2005
New England States, Women, Women's health, New England, Health counseling, Health counselling

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Patents versus patients? Antiretroviral therapy in India

Article Abstract:

The President of India issued a patent-amendment ordinance requiring 20-year patents on all new medications, which came into effect from January 1, 2005. Advocacy groups aroused many objections around the world for patients with human immunodeficiency virus (HIV) infection, who differentiated the proposed law as pitting patents against patients.

Author: Havlir, Diane V., Hammer, Scott M.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2005
United States, India, Health aspects, Antiviral agents, Antiretroviral agents

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: HIV infection, Drug therapy, HIV infections
Similar abstracts:
  • Abstracts: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
  • Abstracts: Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection
  • Abstracts: Assessing mixed venous and arterial leg ulcers. Diagnosing, treating, and delivering care for people with venous leg ulcers
  • Abstracts: Mitochondrial abnormalities in HIV-infected lipoatrophic patients treated with antiretroviral agents. Efficacy and tolerability of a nucleoside reserve transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients
  • Abstracts: Screening healthy infants for iron deficiency using reticulocyte hemoglobin content. Reticulocyte Hemoglobin Content to Diagnose Iron Deficiency in Children
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.